Scientists have discovered a way to distinguish pancreatic cancer from non-cancerous tissue, new research shows.
The method may also distinguish patients who will survive longer than two years.
The research examined pancreatic cancer cells for tiny molecules called microRNA (miRNA). It shows that relative levels of certain miRNAs can distinguish pancreatic cancer from nearby noncancerous tissue and from inflamed pancreatic tissue.
The study by researchers at Ohio State University Comprehensive Cancer Center, is published in the May 2 issue of the Journal of the American Medical Association.
"Our findings suggest that miRNAs might help detect the disease earlier and differentiate it from noncancerous conditions," says first author Mark Bloomston, assistant professor of surgery at Ohio State's James Cancer Hospital and Solove Research Institute.
"We also found that we could predict which patients would do better or worse based on a just a few miRNAs. Such correlations with survival have previously been lacking in pancreatic cancer," Bloomston says.
Pancreatic cancer is expected to strike 37,170 Americans and to kill 33,370 others this year, making it the fourth-leading cause of cancer death in both men and women. The number of new cases nearly equals the number of deaths because the disease is difficult to diagnosis early and because there have been few treatment advances.
For this study, Bloomston and his colleagues examined tumor samples from 65 patients with adenocarcinoma of the pancreas, the most common form of the disease.
They extracted miRNA from isolated tumor cells and from adjacent noncancerous pancreatic tissue. In addition, they isolated miRNA from the pancreatic cells of people who had undergone surgery for chronic pancreatitis, an inflammation of the pancreas often associated with pancreatic cancer.
Perhaps surprisingly, the miRNAs that could discriminate between long- and short-term survivors were not among those that were specific to pancreatic cancer.
"These miRNAs have not been studied much, so we don't know how important they will ultimately be," Bloomston says. "Our findings are really just a starting point. Now we and others need to validate the role of these molecules in pancreatic cancer and to study what they do."
MicroRNAs, first discovered less than 15 years ago, help control the type and quantity of proteins that cells naturally make by modifying other genes. Research over the past few years has shown that they also play an important role in cancer. More than 300 different human miRNAs have been identified so far.
Source: Ohio State University
Related stories:
Micro molecules can identify pancreatic cancer
A pattern of micro molecules can distinguish pancreatic cancer from normal and benign pancreatic tissue, new research suggests.
Researchers study prevention of blood clots in cancer patients
As more individuals with cancer are being treated as outpatients, the University of Rochester Medical Center is working on an emerging problem: how to prevent the life-threatening blood clots that can accompany some newer cancer drugs.
Hepatitis B exposure may increase risk for pancreatic cancer
In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer.
Scientists deliver toxic genes to effectively kill pancreatic cancer cells
A research team, led by investigators at the Department of Surgery at Jefferson Medical College of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, has achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene. The findings – set to be published in the October issue of
Cancer Biology & Therapy – reflect the first time this unique strategy has been tested in pancreatic cancer cells, and the success seen offers promise for future pre-clinical animal studies, and possibly, a new clinical approach.
New options when an old enemy returns
Pancreatic cancer is one of the most challenging malignancies to treat, and recurrence is common, even after initial treatment with surgery and radiation. When the cancer does return, treatment options are often limited to chemotherapy, but researchers at Georgetown's Lombardi Comprehensive Cancer Center are utilizing the precision allowed by CyberKnife® to see if radiosurgery is a viable treatment option in select patients.
New drug substantially extends survival in pancreatic cancer
A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, researchers report at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.
Anti-tumor therapy with endoscopic ultrasound may fight cancer more safely and effectively
The chairman of EUS2008 today announced that investigational research on a therapeutic technique that will allow physicians to directly inject malignant tumors with cancer fighting agents from inside the body will be presented at the 16th International Symposium of Endoscopic Ultrasonography (EUS2008) in San Francisco on September 12-13.
Antiangiogenic drugs impede chemotherapy-stimulated tumor recovery
Scientists have gained new insight into a mechanism whereby chemotherapy may actually assist the rapid regrowth of tumors after treatment. The research, published by Cell Press in the September issue of the journal
Cancer Cell, also helps to explain why a combination of traditional chemotherapy with drugs that block formation of new blood vessels might impede the devastating tumor recovery that often follows cancer therapy.